专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5441883A A3 adenosine receptor, DNA, and uses 失效
标题翻译： A3腺苷受体，DNA和用途
公开(公告)号：US5441883A
公开(公告)日：1995-08-15
申请号：US101435
申请日：1993-08-02
申请人： Olivier Civelli , Qun-Yong Zhou
发明人： Olivier Civelli , Qun-Yong Zhou
IPC分类号： A61K38/00 , C07K14/705 , C12N15/12
CPC分类号： C07K14/705 , A61K38/00
摘要： The present invention relates to a novel mammalian adenosine receptor. The invention is directed toward the isolation, characterization and pharmacological use of the rat A3 adenosine receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing the rat A3 adenosine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize the rat A3 adenosine receptor. The invention also provides methods for screening adenosine-receptor agonists and antagonists in vitro using preparations of the rat A3 adenosine receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the rat A3 adenosine receptor gene.
摘要翻译：本发明涉及新型哺乳动物腺苷受体。本发明涉及大鼠A3腺苷受体（对应于该受体的基因）的分离，表征和药理学应用，能够在转化的真核细胞的培养物中表达大鼠A3腺苷受体的重组真核表达构建体，合成大鼠A3腺苷受体的真核细胞。本发明还提供了使用由包含大鼠A3腺苷受体基因的重组真核表达构建体转化的真核细胞的这种培养物中的大鼠A3腺苷受体的制备体外筛选腺苷受体激动剂和拮抗剂的方法。

2. 发明授权

US07259240B2 Primate prokineticin receptor polypeptides 有权
标题翻译：灵长类动蛋白受体多肽
公开(公告)号：US07259240B2
公开(公告)日：2007-08-21
申请号：US10977113
申请日：2004-10-29
申请人： Qun-Yong Zhou
发明人： Qun-Yong Zhou
IPC分类号： C07K14/705
CPC分类号： C07K14/705 , C07K14/47
摘要： The invention provides an isolated squirrel monkey prokineticin receptor 2 (PKR2) polypeptide containing the amino acid sequence referenced as SEQ ID NO:2. The invention also provides an isolated chimpanzee PKR2 containing the amino acid sequence referenced as SEQ ID NO:4. Also provided are methods of identifying PKR2 agonists and antagonists using the squirrel monkey PKR2 polypeptide. Additionally, the invention provides an isolated rhesus monkey PK2 polypeptide containing the amino acid sequence referenced as SEQ ID NO:6. Nucleic acid molecules encoding the disclosed polypeptides further are provided by the invention.
摘要翻译：本发明提供了含有SEQ ID NO：2所示的氨基酸序列的分离的松鼠猴促动蛋白受体2（PKR2）多肽。本发明还提供了包含SEQ ID NO：4所示的氨基酸序列的分离的黑猩猩PKR2。还提供了使用松鼠猴PKR2多肽鉴定PKR2激动剂和拮抗剂的方法。另外，本发明提供了含有SEQ ID NO：6所示的氨基酸序列的分离的恒河猴PK2多肽。编码所公开的多肽的核酸分子进一步由本发明提供。

3. 发明申请

US20050170455A1 Novel prokineticin receptor isoforms and methods of use 审中-公开
标题翻译：新的原肌动蛋白受体异构体和使用方法
公开(公告)号：US20050170455A1
公开(公告)日：2005-08-04
申请号：US10871152
申请日：2004-06-18
申请人： Qun-Yong Zhou
发明人： Qun-Yong Zhou
IPC分类号： C07H21/04 , C07K20060101 , C07K14/705 , C07K14/72 , C07K16/28
CPC分类号： C07K14/723
摘要： The invention provides an isolated prokineticin receptor 2 long isoform polypeptide that contains an amino acid sequence selected from the amino acid sequences referenced as SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4. Also provided is an isolated prokineticin receptor 2 short isoform polypeptide, which contains the amino acid sequence referenced as SEQ ID NO:5. Also provided is further prokineticin 2 short isoform polypeptide containing the sequence of SEQ ID NO:17. Further provided is an isolated prokineticin receptor 1 short isoform polypeptide that contains the amino acid sequence referenced as SEQ ID NO:6. The invention also provides methods for preparing an isolated polypeptide corresponding to a long or short PKR isoform of the invention; as well as antibodies That selectively bind to a long or short PKR isoform of the invention. Methods for identifying agonists and antagonists of PKR1 and PKR2 further are provided by the invention.
摘要翻译：本发明提供了分离的原动力蛋白受体2长同种型多肽，其含有选自SEQ ID NO：2，SEQ ID NO：3或SEQ ID NO：4的氨基酸序列的氨基酸序列。还提供了分离的原动力蛋白受体2短同种型多肽，其含有以SEQ ID NO：5表示的氨基酸序列。还提供了含有SEQ ID NO：17的序列的进一步原肌动蛋白2短型同种型多肽。还提供了含有SEQ ID NO：6所示的氨基酸序列的分离的原肌动蛋白受体1短异构体多肽。本发明还提供了制备对应于本发明的长或短PKR同种型的分离的多肽的方法; 以及选择性结合本发明的长或短PKR同种型的抗体。用于鉴定PKR1和PKR2激动剂和拮抗剂的方法进一步由本发明提供。

4. 发明授权

US07115560B2 Methods for modulating gastric secretion using prokineticin receptor antagonists 有权
标题翻译：使用原肌动蛋白受体拮抗剂调节胃分泌的方法
公开(公告)号：US07115560B2
公开(公告)日：2006-10-03
申请号：US10811328
申请日：2004-03-25
申请人： Qun-Yong Zhou
发明人： Qun-Yong Zhou
IPC分类号： C07K14/00
CPC分类号： C07K14/47
摘要： The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:3, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:3, and (b) from 0 to 9 of amino acids 78 to 86 of SEQ ID NO:3, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21). In another embodiment, the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:6, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:6, and (b) from 0 to 4 of amino acids 78 to 81 of SEQ ID NO:6, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21).
摘要翻译：本发明提供了通过施用一定量的有效改变一种或多种胃酸分泌标记的促动素原受体拮抗剂调节胃酸分泌的方法，其中所述拮抗剂含有与氨基酸至7至77个至少80％相同的氨基酸序列其包含（a）SEQ ID NO：3的10个保守的半胱氨酸残基和（b）SEQ ID NO：3的氨基酸78至86的0至9，其中氨基酸1至 6的拮抗剂不由氨基酸AVITGA（SEQ ID NO：21）组成。在另一个实施方案中，拮抗剂含有与SEQ ID NO：6的氨基酸至7至77至少80％相同的氨基酸序列，其包括（a）SEQ ID NO：6的10个保守的半胱氨酸残基，和（b ）SEQ ID NO：6的氨基酸78至81的0至4，其中拮抗剂的氨基酸1至6不由氨基酸AVITGA（SEQ ID NO：21）组成。

5. 发明申请

US20050026828A1 Methods for modulating gastric secretion using prokineticin receptor antagonists 有权
标题翻译：使用原肌动蛋白受体拮抗剂调节胃分泌的方法
公开(公告)号：US20050026828A1
公开(公告)日：2005-02-03
申请号：US10811328
申请日：2004-03-25
申请人： Qun-Yong Zhou
发明人： Qun-Yong Zhou
IPC分类号： A61K20060101 , A61K38/17 , A61P1/04 , C07K14/00 , C07K14/47
CPC分类号： C07K14/47
摘要： The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:3, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:3, and (b) from 0 to 9 of amino acids 78 to 86 of SEQ ID NO:3, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21). In another embodiment, the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:6, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:6, and (b) from 0 to 4 of amino acids 78 to 81 of SEQ ID NO:6, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21).
摘要翻译：本发明提供了通过施用一定量的有效改变一种或多种胃酸分泌标记的促肌酸激素受体拮抗剂调节胃酸分泌的方法，其中拮抗剂含有与氨基酸至7至77至少80％相同的氨基酸序列其包含（a）SEQ ID NO：3的10个保守的半胱氨酸残基和（b）SEQ ID NO：3的氨基酸78至86的0至9，其中氨基酸1至 6的拮抗剂不由氨基酸AVITGA（SEQ ID NO：21）组成。在另一个实施方案中，拮抗剂含有与SEQ ID NO：6的氨基酸至7至77至少80％相同的氨基酸序列，其包括（a）SEQ ID NO：6的10个保守的半胱氨酸残基，和（b ）SEQ ID NO：6的氨基酸78至81的0至4，其中拮抗剂的氨基酸1至6不由氨基酸AVITGA（SEQ ID NO：21）组成。

6. 发明申请

US20120035149A1 Prokineticin Receptor Antagonists And Uses Thereof 有权
标题翻译：原肌动蛋白受体拮抗剂及其用途
公开(公告)号：US20120035149A1
公开(公告)日：2012-02-09
申请号：US13140314
申请日：2009-12-16
申请人： Qun-Yong Zhou , Jia-Da Li , Qi Huang
发明人： Qun-Yong Zhou , Jia-Da Li , Qi Huang
IPC分类号： A61K31/397 , C07D405/12 , C07D417/12 , C07D405/14 , C07D471/04 , C07D413/12 , C07D407/12 , A61K31/357 , A61K31/4427 , A61K31/4025 , A61K31/4523 , A61K31/541 , A61K31/496 , A61K31/404 , A61K31/437 , A61K31/5377 , A61P3/10 , A61P25/20 , A61P9/10 , A61P1/00 , A61P25/04 , A61P25/22 , A61P25/00 , C07D321/10
CPC分类号： C07D321/10 , C07D405/12 , C07D417/12
摘要： Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes.
摘要翻译：提出了促动蛋白拮抗剂的考虑的化合物，组合物和方法，其中促动蛋白拮抗剂用于治疗和预防各种病症和障碍，特别是II型糖尿病。

7. 发明授权

US08101158B1 Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity 有权
标题翻译：治疗脑血管疾病的方法，包括施用抑制原肌动蛋白受体活性的药剂
公开(公告)号：US08101158B1
公开(公告)日：2012-01-24
申请号：US12025673
申请日：2008-02-04
申请人： Qun-Yong Zhou , Alex G. Lee , Michelle Y. Cheng , Robert M. Sapolsky
发明人： Qun-Yong Zhou , Alex G. Lee , Michelle Y. Cheng , Robert M. Sapolsky
IPC分类号： A61K49/00 , A61K31/535
CPC分类号： A61K31/5377 , A61K9/0019
摘要： The present invention relates to a method of identifying agents that modulate prokineticin receptors, particularly, in the brain. Such agents are useful in the treatment of cerebrovascular diseases, including cerebral ischemia, cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, and ischemic reperfusion injury. Additionally, such agents are useful to treat seizure disorders, such as epilepsy.
摘要翻译：本发明涉及一种鉴定调节原肌动蛋白受体，特别是在脑中的药剂的方法。这些药物可用于治疗脑血管疾病，包括脑缺血，脑出血，缺血性卒中，出血性中风和缺血再灌注损伤。此外，这些药剂可用于治疗癫痫发作，例如癫痫。

8. 发明申请

US20070066530A1 Methods for modulating gastric secretion using prokineticin receptor antagonists 审中-公开
标题翻译：使用原肌动蛋白受体拮抗剂调节胃分泌的方法
公开(公告)号：US20070066530A1
公开(公告)日：2007-03-22
申请号：US11529695
申请日：2006-09-27
申请人： Qun-Yong Zhou
发明人： Qun-Yong Zhou
IPC分类号： A61K38/17
CPC分类号： C07K14/47
摘要： The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:3, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:3, and (b) from 0 to 9 of amino acids 78 to 86 of SEQ ID NO:3, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21). In another embodiment, the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ ID NO:6, which includes (a) the 10 conserved cysteine residues of SEQ ID NO:6, and (b) from 0 to 4 of amino acids 78 to 81 of SEQ ID NO:6, wherein amino acids 1 to 6 of the antagonist do not consist of amino acids AVITGA (SEQ ID NO:21).
摘要翻译：本发明提供了通过施用一定量的有效改变一种或多种胃酸分泌标记的促动素原受体拮抗剂调节胃酸分泌的方法，其中所述拮抗剂含有与氨基酸至7至77个至少80％相同的氨基酸序列其包含（a）SEQ ID NO：3的10个保守的半胱氨酸残基和（b）SEQ ID NO：3的氨基酸78至86的0至9，其中氨基酸1至 6的拮抗剂不由氨基酸AVITGA（SEQ ID NO：21）组成。在另一个实施方案中，拮抗剂含有与SEQ ID NO：6的氨基酸至7至77至少80％相同的氨基酸序列，其包括（a）SEQ ID NO：6的10个保守的半胱氨酸残基，和（b ）SEQ ID NO：6的氨基酸78至81的0至4，其中拮抗剂的氨基酸1至6不由氨基酸AVITGA（SEQ ID NO：21）组成。

9. 发明申请

US20050074758A1 Prokineticin polypeptides, related compositions and methods 审中-公开
标题翻译：原肌动蛋白多肽，相关组合物和方法
公开(公告)号：US20050074758A1
公开(公告)日：2005-04-07
申请号：US10415724
申请日：2001-11-01
申请人： Qun-Yong Zhou , Frederick Ehlert
发明人： Qun-Yong Zhou , Frederick Ehlert
IPC分类号： G01N33/50 , A61K38/00 , A61K39/00 , A61P1/00 , A61P29/00 , A61P31/00 , A61P35/00 , C07K14/47 , C07K16/18 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12Q1/02 , G01N33/15 , G01N33/53 , G01N33/566 , C12Q1/68 , C07H21/04
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00
摘要： The invention provides isolated polypeptides that stimulate gastroeintestinal smooth muscle contraction, including human prokineticin 1 and human prokineticin 2 polypeptides, and functional fragments and modifications thereof. Also provided are methods of stimulating gastrointestinal smooth muscle contraction in a mammal, by administering to the mammal an effective amount of a prokineticin polypeptide. The invention also provides nucleic acid molecules encoding a prokineticin polypeptide, and antibodies that selectively bind a prokineticin polypeptide. Further provided are methods of identifying a prokineticin receptor ligand, agonist or antagonist.
摘要翻译：本发明提供刺激胃肠道平滑肌收缩的分离的多肽，包括人原肌动蛋白1和人原肌动蛋白2多肽，及其功能片段和修饰。还提供了通过向哺乳动物施用有效量的促动蛋白多肽来刺激哺乳动物的胃肠平滑肌收缩的方法。本发明还提供编码促动蛋白多肽的核酸分子和选择性结合原动力蛋白多肽的抗体。进一步提供了鉴定促动蛋白受体配体，激动剂或拮抗剂的方法。

10. 发明申请

US20100286021A1 Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders 审中-公开
标题翻译：调节原肌动蛋白2治疗应激反应和焦虑相关疾病的方法
公开(公告)号：US20100286021A1
公开(公告)日：2010-11-11
申请号：US12679471
申请日：2008-09-25
申请人： Qun-Yong Zhou , Jia-Da Li
发明人： Qun-Yong Zhou , Jia-Da Li
IPC分类号： C07K14/00 , G01N33/50 , A61P25/22
CPC分类号： A61K38/1709 , G01N33/566 , G01N2333/726 , G01N2500/04 , G01N2800/301 , G01N2800/7004
摘要： The invention is based on the discovery that an effective therapeutic strategy for ameliorating the symptoms of anxiety-related disorders can be achieved by decreasing levels of PK2 and administering an effective amount of PK2 receptor antagonist. A method of modulating the behavioral response of a subject displaying symptoms of stress responses and/or anxiety-related disorders is disclosed. The disclosed methods indicate that PK2 is an essential regulator of behavioral stress response independent of HPA.
摘要翻译：本发明基于以下发现：通过降低PK2的水平并施用有效量的PK2受体拮抗剂，可以实现改善焦虑相关疾病症状的有效治疗策略。公开了调节显示压力反应和/或焦虑相关疾病症状的受试者的行为反应的方法。所公开的方法表明PK2是独立于HPA的行为应激反应的基本调节剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式